Review
Immunology
Maryam Nikoonezhad, Maryam Vahdat Lasemi, Shahram Alamdari, Mozhdeh Mohammadian, Mehdi Tabarraee, Mojtaba Ghadyani, Mohsen Hamidpour, Elham Roshandel
Summary: Type 1 diabetes is an autoimmune disease that can be effectively treated with autologous hematopoietic stem cell transplantation. This treatment provides lasting remission and is superior to other immunotherapies in clinical efficacy.
TRANSPLANT IMMUNOLOGY
(2022)
Review
Immunology
Ida Pastore, Emma Assi, Moufida Ben Nasr, Andrea Mario Bolla, Anna Maestroni, Vera Usuelli, Cristian Loretelli, Andy Joe Seelam, Ahmed Abdelsalam, Gian Vincenzo Zuccotti, Francesca D'Addio, Paolo Fiorina
Summary: Although progress has been made in understanding the pathophysiological mechanisms of T1D, the quest for effective therapeutic options is ongoing. Promising results have been seen with HSC-based approaches and teplizumab, but more research is needed to establish their long-term efficacy and safety. Genetically engineered HSCs hold potential as a novel biologic therapy for T1D and other autoimmune/immune-related disorders, with studies in murine models and humanized mouse models showing accelerated translational potentials.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Endocrinology & Metabolism
Xin-Xing Wan, Dan-Yi Zhang, Md. Asaduzzaman Khan, Sheng-Yuan Zheng, Xi-Min Hu, Qi Zhang, Rong-Hua Yang, Kun Xiong
Summary: This review article discusses the application of stem cell transplantation in the treatment of type 1 diabetes mellitus (T1DM). Stem cells have the potential to reestablish immunotolerance and preserve islet beta-cell function, providing a promising alternative for T1DM treatment.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Wei Hu, Xiang Song, Haibo Yu, Jingyu Sun, Hongjun Wang, Yong Zhao
Summary: This review summarizes the current research progress of stem cell-derived extracellular vesicles (EVs) for the treatment of type 1 diabetes (T1D), suggesting their potential as novel therapeutic agents for autoimmune diseases.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Multidisciplinary Sciences
Todd M. Brusko, Holger A. Russ, Cherie L. Stabler
Summary: Advancements in blood glucose monitoring and therapeutic insulin administration have improved the quality of life for individuals with type 1 diabetes, but still fall short of the metabolic control provided by native islets. Integrated advancements in islet cell replacement and immunomodulatory therapies are offering hope for the restoration of endogenous glucose regulation. Progress in stem cell biology and graft site design are providing innovative sources for cellular material and improved engraftment.
Review
Engineering, Biomedical
Magdalena M. Samojlik, Cherie L. Stabler
Summary: Effective suppression of adaptive immune responses is crucial for the success of allogeneic cell therapies, especially in the presence of pre-existing autoimmunity. Current immunosuppressive agents used in islet transplantation show limitations in controlling memory T cell populations, leaving the graft vulnerable. Biomaterials have the potential to provide local and nuanced instruction to suppress immune pathways and improve the efficacy of cell therapy.
ACTA BIOMATERIALIA
(2021)
Review
Endocrinology & Metabolism
Daniel J. Drucker
Summary: Scientific advancements in the treatment of type 1 diabetes have seen significant progress in recent decades. Innovations such as newer insulin analogues, smart insulins, oral and weekly insulins, as well as strategies for human beta cell replacement and immune manipulation, have potential to improve quality of life for patients.
Review
Immunology
Qi Zhang, Carmen Gonelle-Gispert, Yanjiao Li, Zhen Geng, Sandrine Gerber-Lemaire, Yi Wang, Leo Buhler
Summary: Islet transplantation is a promising approach for treating type 1 diabetes, but there are challenges of immune response and long-term use of immunosuppression. Encapsulation of islets in semi-permeable biomaterials allows long-term graft survival while preventing immune response. Researchers have developed various strategies, including encapsulating porcine islets and co-encapsulation with other cells or ingredients, to improve the functionality of transplanted islets. Hydrogels, both natural and synthetic, have been widely used for cell encapsulation and therapeutic applications.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Ji Sun, Jingbo Li, Zhikun Huan, Stephen J. Pandol, Dechen Liu, Luoran Shang, Ling Li
Summary: Type 1 diabetes mellitus is characterized by autoimmune damage of pancreatic beta cells. This study develops mesenchymal stem cell (MSC)-laden composite beta cell porous microgels (MGs) to address sustainability for the treatment of diabetes. The results demonstrate that the MGs have great potential for the treatment of diabetes providing a promising platform for clinical beta cell transplantation.
ADVANCED FUNCTIONAL MATERIALS
(2023)
Review
Medicine, Research & Experimental
Tobias Alexander, Raffaella Greco, John A. Snowden
Summary: The introduction of targeted biologic therapies has significantly changed the treatment landscape for autoimmune diseases, but these therapies require continuous administration and are not curative. Hematopoietic stem cell transplantation aims to provide treatment-free remissions by reinducing self-tolerance and has become an important part of treatment algorithms for various autoimmune diseases. Recent data has improved the evidence base to support autologous HSCT in multiple sclerosis, systemic sclerosis, Crohn's disease, and other rare disease indications.
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021
(2021)
Review
Chemistry, Multidisciplinary
Debkalpa Goswami, Daniel A. Domingo-Lopez, Niamh A. Ward, Jeffrey R. Millman, Garry P. Duffy, Eimear B. Dolan, Ellen T. Roche
Summary: Stem cell derived insulin producing cells or islets show promise in reversing Type 1 Diabetes (T1D), but successful transplantation currently requires long-term modulation with immunosuppressant drugs. An alternative approach to avoid immune response is to use an islet macroencapsulation device. These systems must meet stringent design criteria to achieve the ultimate goal of reversing T1D.
Review
Immunology
Susanna Esposito, Elena Mariotti Zani, Lisa Torelli, Sara Scavone, Maddalena Petraroli, Viviana Patianna, Barbara Predieri, Lorenzo Iughetti, Nicola Principi
Summary: Type 1 diabetes is the most common pediatric endocrine disease with an increased infection risk and lower immune response to vaccines; further research is needed to establish the most effective and safe vaccine use in this population.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell & Tissue Engineering
Yanju Li, Feiqing Wang, Huiling Liang, Dongxin Tang, Mei Huang, Jianing Zhao, Xu Yang, Yanqing Liu, Liping Shu, Jishi Wang, Zhixu He, Yang Liu
Summary: The meta-analysis included 10 studies with a total of 239 participants, evaluating the efficacy of mesenchymal stem cells (MSCs) therapy in treating diabetes mellitus. The results showed that MSC treatment led to significantly lower HbA1c levels, higher fasting C-peptide levels, and reduced insulin requirement in T1DM patients.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Oncology
Tobias Alexander, John A. Snowden, Joachim Burman, Hyun-Dong Chang, Nicoletta Del Papa, Dominique Farge, James O. Lindsay, Florent Malard, Paolo A. Muraro, Rosamaria Nitti, Azucena Salas, Basil Sharrack, Mohamad Mohty, Raffaella Greco
Summary: Hematopoietic stem cell transplantation (HSCT) has been evolving as a specific treatment for severe and refractory autoimmune diseases, with studies showing the important role of intestinal microbiota in shaping immune response and predicting treatment outcomes. Therapeutic interventions such as fecal microbiota transplant have emerged as promising approaches for restoring intestinal microbiota integrity post-transplantation.
FRONTIERS IN ONCOLOGY
(2021)
Review
Immunology
S. Alice Long, Jane H. Buckner
Summary: This review examines the current understanding of the etiology of Type 1 diabetes (T1D), focusing on the role of immune cells in the progression of the disease. It also highlights how this knowledge is driving the development of immunotherapies for the prevention and treatment of T1D.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2022)